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Conclusion. These findings indicate that efficient predniso-Older boys benefit from higher initial prednisolone therapy
lone doses may vary between sexes and ages, and that a higherfor nephrotic syndrome.
initial prednisolone therapy may be of greater benefit to olderBackground. A long course of the initial prednisolone ther-
boys.apy has been shown to be more effective than standard-course
therapy in reducing relapse rates in children with idiopathic
nephrotic syndrome, but it is commonly accompanied by corti-
costeroid toxicities. There has been no study on prednisolone Approximately 80% of idiopathic nephrotic syndromedosage for the effective treatment of nephrotic syndrome.
in childhood is ascribed to minimal-change nephroticMethods. Sixty-eight children (42 boys and 26 girls) with an
syndrome [1, 2]. Almost the same percentage of childreninitial attack of nephrotic syndrome were randomly allocated
into two different long-course treatment groups. Patients in with idiopathic nephrotic syndrome respond to cortico-
Group 1 received a daily prednisolone dose of 60 mg/m2 for steroid therapy [3]. Corticosteroid responsiveness is
six weeks, followed by an alternate-day dose of 40 mg/m2 for known as a better predictor of a good prognosis of renalsix weeks. Patients in Group 2 had a daily dose of 40 mg/m2
function than renal histology in children with idiopathicinstead of 60 mg/m2.
nephrotic syndrome [4]. Corticosteroids are thereforeResults. Four children in each group did not respond within
six weeks. Group 1 was associated with a significantly earlier administered to these nephrotic children without histo-
response but more frequent corticosteroid toxicities than logic examination whose proteinuria usually disappears
Group 2. Boys in Group 1 had a higher rate of sustained within four weeks after initiation of corticosteroid ther-remission than boys in Group 2 (P 5 0.0073), especially boys
apy [1]. However, these steroid-responsive nephrotic chil-four years old or more (P 5 0.0027), but girls did not show a
dren often have relapses and develop corticosteroid tox-significant difference (P 5 0.863). Boys four years old or more
in Group 1 had a course of frequent relapsing less often than icities. Therefore, it is desirable to determine a more ideal
those in Group 2 (2 of 13 vs. 6 of 8, P 5 0.0075). corticosteroid dosage that is effective enough to prevent
relapses and also have the least amount of toxicity. To
date, control studies on prednisolone dosages are lim-1 Contributing members (centers) of the West Japan Cooperative Study
ited, so the most efficient prednisolone regimens are yetof Kidney Disease in Children: K. Furusho, S. Itoh, and Y. Nakazawa
(Kyoto); E. Kato, K. Konishi, and M. Shima (Fukui); K. Nishioka (Otsu); to be established.
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weeks) is the standard regimen popularly used as ansyndrome, gender and ESRD, proteinuria, frequent relapse of ne-
phrotic syndrome, dose of prednisolone. initial prednisolone therapy for children with newly on-
set idiopathic nephrotic syndrome [2]. Recent controlledReceived for publication December 2, 1998
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regimen [5–8]. However, long-course prednisolone regi- cluding moon face, obesity, glaucoma, cataracts, hyper-
tension, striae, psychological disturbance, hirsutism, ste-mens have been more frequently associated with cortico-
steroid toxicities than the standard-course regimen [7]. roid acne, and others, were regularly checked during and
at completion of corticosteroid administration.Whether a standard daily dose of 60 mg/m2 is required
for sufficient therapeutic efficacy remains to be studied. Relapse was diagnosed when proteinuria of 21 or
more continued for three consecutive days. Patients ofOn this point, it should be mentioned that adults with
minimal-change nephrotic syndrome are usually treated both groups who relapsed after two months or more
following completion of the previous prednisolone coursewith lower doses of prednisolone (1 mg/kg/day [9] or 30
to 60 mg/day [10, 11]) than children, and they have a were treated with the moderate regimen. Relapses within
the first two months after completion of the previouscomparable, good response to corticosteroids. These find-
ings suggest that lower daily doses of prednisolone may prednisolone treatment were treated with the long-term
prednisolone regimen, since children with early relapsesalso be effective for children with idiopathic nephrotic
syndrome and are associated with less corticosteroid tox- tend to have frequent relapses [5]. The long-term predni-
solone regimen comprised a daily dose of 40 mg/m2 givenicity. Some authors also observed that nephrotic children
of young age at the onset of the disease or of male sex for four weeks, tapering by 25% every two weeks with
a total daily course of 12 weeks, followed by the alternatefrequently have relapses [12, 13]. These findings also raise
the possibility that the most efficient dose for management day dose of 40 mg/m2 for six months with a tapering
dose over another three months. In the present study,of the disease may vary considerably with sex and age.
We investigated, in a multicenter randomized con- frequent relapsers were defined as those who had re-
lapses two or more times consecutively within the firsttrolled study, whether the daily dose of prednisolone in
the intensive long-course regimen (60 mg/m2 for six weeks) two months after completion of the previous predniso-
lone therapy, and steroid dependence was defined asused in Ehrich and Brodehl’s study could be lowered to
40 mg/m2/day with sufficient effectiveness for the man- those who had relapses two or more times consecutively
during the prednisolone treatment or within the firstagement of idiopathic nephrotic syndrome in children
[7]. We also analyzed differences in the efficacy of the two weeks after completion of the previous prednisolone
therapy [5], since patients were treated longer in thetwo regimens between sexes and ages.
present study than in that of the ISKDC [2, 15]. All
patients except one completed a two-year follow-up pe-METHODS
riod from the end of the initial treatment. One girl in
The subjects comprised 42 boys and 26 girls, aged 1.5 Group 2 became a frequent relapser and could not be
to 14.4 years, who had had an initial attack of idiopathic followed up subsequently because she moved, receiving
nephrotic syndrome between December 93 and August medical care in another place.
96. The study protocol was in accordance with the stan- Clinical characteristics at onset, the days required for
dards of the ethics committee at each center, and all remission with the initial prednisolone regimen, and the
parents of these patients gave informed consent. Children rates of sustained remission (defined as having no re-
were allocated at random into two groups. Group 1 re- lapse) after completion of initial daily prednisolone course
ceived a daily dose of 60 mg/m2 in three divided doses were compared between the two groups. Corticosteroid
(maximum dose 80 mg/day) for six weeks, followed by toxicities were compared between the two groups ac-
the alternate-day, single morning dose of 40 mg/m2 (max- cording to the incidence of individual toxicity symptoms
imum dose 60 mg/day) for six weeks. Children in Group 2 and also the total number of toxicities that developed.
were treated with a daily dose of 40 mg/m2 in three divided Differences in effectiveness between the two regimens
doses (maximum dose 60 mg/day) for six weeks, followed were also analyzed for each sex and then for two sub-
by an alternate-day, single morning dose of 40 mg/m2 groups in boys (,4 years and $4 years) [13]. The statisti-
(maximum dose 60 mg/day) for six weeks. Patients and cal methods used were the unpaired t-test, chi-square
their parents were informed about the adverse side effects test, Fisher’s exact probability test, the Mann–Whitney
of corticosteroid treatment and were advised to restrict test, and the Kaplan–Meier life table method using a log
their salt intake to below 1 g/day until remission, and rank test. A two-tailed P value of less than 0.05 was
between 1 and 5 g/day together with avoidance of caloric taken as the level of significance.
overintake after remission, until the completion of the
prednisolone therapy. Remission was defined as the dis-
RESULTSappearance of proteinuria [urinary protein ,4 mg/h/m2
or albusticks (2) or (6)] for at least three consecutive There were no differences in clinical characteristics at
onset of the nephrotic syndrome between groups 1 and 2,days [14, 15]. Patients were admitted to the hospital
during treatment, at least while they were given a daily as shown in Table 1.
The same percentage of children (30 of the 34 chil-prednisolone dose. Corticosteroid toxicity symptoms, in-
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Table 1. Clinical characteristics of the patients at onset of the
nephrotic syndrome in Groups 1 and 2
Group 1 Group 2
Number of patients 34 34
Male/female 21/13 21/13
Age years 6.463.4 7.164.0
Serum albumin g/dL
(normal, 4.660.7 g/dL) 1.860.6 1.760.5
Serum total cholesterol mg/dL
(normal, 170625 mg/dL) 4726133 4746130
Fig. 2. Incidence of corticosteroid toxicities between Groups 1 ( )
and 2 ( ) during the initial prednisolone therapy in 60 patients who
responded to the prednisolone therapy.
Fig. 1. Cumulative percentage of patients with remission of nephrotic
syndrome on days after beginning prednisolone therapy. Data are pre-
sented for 60 of 68 children who responded to steroids. The days re-
quired for remission were significantly longer in Group 2 (thin line, N 5
30) than in Group 1 (thick line, N 5 30). P , 0.05, log rank test.
Fig. 3. Cumulative rate of the children with sustained remission two
years after completion of the initial daily prednisolone in Groups 1
(thick line; N 5 30) and 2 (thin line; N 5 30). Group 1 had a higher
cumulative rate of children with sustained remission than Group 2 (P 5dren) in the two groups responded to the prednisolone
0.046, log rank test).course within six weeks. Four children in Group 1
showed partial response, whereas two of the four chil-
dren in Group 2 showed no response, and the others
had a partial response. in Group 2 (P , 0.05, chi-square test). Although there
was no significant difference in the incidence of eachThe days required for remission were significantly
longer in Group 2 than in Group 1 (P , 0.05, log rank of the other corticosteroid toxicities between the two
regimens, the total number of toxicities appearing intest), with an average of 11.4 6 4.0 versus 9.6 6 2.6 days
(SD), respectively (Fig. 1). There was no difference in Group 1 was greater than in Group 2 (2.0 6 1.2 vs. 1.1 6
1.1, P , 0.01, unpaired t-test). The side effects werethe days required for remission between sexes or the
two age subgroups (,4 years and $4 years) at onset of usually transient and did not require medical interven-
tion. No patients developed cataracts in either group.the disease (data not shown).
In 2 of the 34 children in Group 1, daily prednisolone Group 1 had a higher cumulative rate of children with
sustained remission than Group 2 during the two yearswas withdrawn in five weeks because of hypertension or
elevated serum LDH levels. These two children were after completion of the initial daily prednisolone course
(P 5 0.046, log rank test; Fig. 3). An analysis betweentreated following the protocol except for the initial daily
prednisolone course. Both relapsed, one in 9 months and the two treatment groups in each sex revealed a definite
difference with a high level of significance in boys butthe other at 15 months after completion of the initial
daily prednisolone course and did not have frequent not in girls: Boys sustained remission more frequently
in Group 1 than in Group 2 (P 5 0.007, log rank test),relapses. Figure 2 shows the incidence of corticosteroid
toxicities during the initial prednisolone regimens in 60 but the two treatment groups of girls showed no differ-
ence (P 5 0.863, log rank test; Fig. 4). Further analysispatients who responded to prednisolone. Children in
Group 1 were accompanied by a higher incidence of between the two treatment groups in each age subgroup
of the 36 boys showed a definite difference with a highglaucoma (intraocular pressure .20 mm Hg) than those
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Table 2. Incidence of six-month remissions between Groups 1
and 2 in sex subgroups and boys aged ,4 and $4 years
Sex Boys
Boys Girls ,4 years $4 years
Group 1a 12/18b 8/12 2/5 10/13c
Group 2a 5/18 7/12 4/10 1/8
a Number of patients who remained in remission at six months after cessation
of the initial daily prednisolone course/number of patients who responded to
steroids
b P 5 0.044 vs. Group 2 (Fisher’s probability test)
c P 5 0.0075 vs. Group 2 (Fisher’s probability test)
Table 3. Incidence of patients with frequent relapses in the total
Fig. 4. Comparison of the cumulative rate of the children with sustained subjects who responded to steroids and in boys aged four
remission between Groups 1 and 2 in each subgroup of boys and girls years or older between Groups 1 and 2
two years after completion of the initial daily prednisolone. A definite
Total subjects Boys$4 yearsdifference was observed in boys (P 5 0.0073) between the two regimens,
but not in girls (P 5 0.863). Symbols are: (solid thin line) Group 1 girls, Group 1 Group 2 Group 1 Group 2
N 5 12; (dashed thin line) Group 2 girls, N 5 12; (solid thick line)
Number of patients 30 30 13 8Group 1 boys, N 5 18; (dashed thick line) Group 2 boys, N 5 12.
Patients with
frequent relapsesa 9 13 2b 6
a Frequent relapsers or steroid-dependent patients
b P 5 0.018 vs. Group 2 (Fisher’s probability test)
7 of 12, respectively, P . 0.999, Fisher’s test; Table 2).
Boys aged four years or more in Group 1 had a much
higher rate of sustained remission than those in Group
2 (10 of 13 vs. 1 of 8, respectively, P 5 0.0075, log rank
test), while boys less than four years of age did not show
a difference between the two prednisolone dose groups
(P . 0.999; Table 2).
Nine (32%) of Group 1 and 13 (43%) of Group 2
patients had frequent relapses (frequent relapsers or ste-
roid-dependent patients) during the follow-up period of
Fig. 5. Cumulative rate of the boys with sustained remission between
33.0 6 8.1 months (mean 6 SD, P 5 0.544, chi-squareGroups 1 and 2 in each subgroup of younger (,4 years old) and older
($4 years old) boys two years after completion of the initial daily test; Table 3). Boys aged four years or more in Group 1
prednisolone. A definite significant difference was found in older boys less often had frequent relapses than those in Group 2
(P 5 0.0027), but not in younger boys (P 5 0.578). Symbols are: (solid
(2 of 13 vs. 6 of 8, respectively, P 5 0.018, Fisher’s test;thin line) Group 1, age ,4 years old, N 5 5; (dashed thin line) Group
2, age ,4 years old, N 5 10; (solid thick line) Group 1, age $4 years Table 3).
old, N 5 13; (dashed thick line) Group 2, age $4 years old, N 5 8.
DISCUSSION
The Group 2 regimen in the present study seemed
level of significance in older boys, but not in younger effective in resolving idiopathic nephrotic syndrome in
boys. Boys aged four years or more had a higher rate children, since the Group 2 regimen induced remission
of sustained remission in Group 1 than in Group 2 (P 5 in the same proportion of children as the Group 1 regi-
0.003, log rank test), whereas comparing the two predni- men. The lower daily dose of prednisolone in Group 2,
solone treatment groups of boys under four years re- however, required a statistically significantly longer time
vealed no different rate of sustained remission (P 5 than the standard daily dose of prednisolone in Group 1
0.578, log rank test; Fig. 5). for remission of the disease. The previous study by Im-
Boys in Group 1 sustained remission more frequently basciati et al observed that more intensive initial immu-
than boys in Group 2 at six months after completion of nosuppressive therapy using pulse methylprednisolone
the initial daily prednisolone course (12 of 18 vs. 5 of doses required less time until remission than the standard
18, respectively, P 5 0.044, Fisher’s test), while girls in oral prednisolone doses [16]. On the other hand, adults
with minimal change nephrotic syndrome, who are usu-Groups 1 and 2 did not show the difference (8 of 12 vs.
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ally treated with a lower daily dose of prednisolone per There are several prednisolone regimens with varying
doses for treatment of children with initial and relapsingbody mass than children, require a longer time than chil-
dren to attain remission with prednisolone therapy [10, 11]. nephrotic syndrome [5, 6, 8, 14]. The treatment of the
idiopathic nephrotic syndrome has a threefold objective:These findings indicate that the days required for remis-
sion may depend on the intensity of the immunosuppres- (1) quick induction of remission of the disease, (2) pre-
vention of relapse, and (3) avoidance of drug side effectssive therapy.
The percentage of children with sustained remission [17]. The Group 2 regimen in the present study was
actually effective in inducing remission, but required aafter the initial treatment in Group 2 was approximately
one half that of Group 1. These results were almost longer time until remission with a lower rate of sustained
remission in comparison to the Group 1 regimen. Onsimilar to those in the Ehrich and Brodehl study, which
compared a standard-course regimen (the standard regi- the other hand, the Group 1 regimen was accompanied
by more corticosteroid toxicities than the Group 2 regi-men in ISKDC) and a long-course regimen (the same
as the Group 1 regimen in the present study) [7]. For men. Some authors prefer intensive regimens because of
less subsequent relapses, while others choose a standardmaintaining remission, the Group 2 regimen in the pres-
ent study had comparable efficacy to the standard-course regimen because of less corticosteroid toxicities. Regi-
mens for frequent relapses such as immunosuppressiveregimen in Ehrich and Brodehl’s study. This may be
explained by the same cumulative daily doses of predni- agents as well as prednisolone have attracted much atten-
tion and have been investigated to reduce relapsing assolone in the two regimens: 40 mg/m2/day for six weeks
vs. 60 mg/m2/day for four weeks, respectively. well as adverse side effects [16, 18–24]. The present study
indicates that prednisolone dosage for initial onset ne-It should be noted that the advantage of the Group 1
regimen over the Group 2 regimen in sustaining remis- phrotic syndrome also affects the subsequent relapse
rate, and that intensive initial prednisolone therapy ap-sion was remarkable in boys in the present study, whereas
the advantage was not observed in girls. It is also striking pears to be of greater benefit in older boys.
that the Group 1 regimen especially benefited boys aged
four years or more at onset for sustaining remission more ACKNOWLEDGMENTS
than the Group 2 regimen did. Boys, especially older The authors are grateful for Dr. Akihiko Seo and Dr. Narufumi
Suganuma (Department of Environmental Health, Fukui Medical Uni-boys, in Group 1 less often had relapses within six months
versity School of Medicine) for their helpful advice on statistical dataafter the initial treatment than those in Group 2. Re-
analysis.
lapses in this period have been found to be a predictor
of subsequent frequent relapses [5, 15]. A smaller portion
REFERENCES
of older boys in Group 1 had a course of frequent relaps-
1. Primary nephrotic syndrome in children: Clinical significance ofing than in Group 2. The difference in effectiveness be-
histopathologic variants of minimal change and of diffuse mesan-
tween the two prednisolone regimens was, thus, most gial hypercellularity: A report of the International Study of Kidney
Disease in Children. Kidney Int 20:765–771, 1981striking with a high level of significance in older boys.
2. Nash M, Edelmann C, Burnstein J, Barnett H: Minimal changePrevious studies of ISKDC found no difference in the
nephrotic syndrome, diffuse mesangial hypercellularity, and focal
incidence of frequent relapsers between sexes or age glomerular sclerosis, in Pediatric Kidney Disease, edited by Edel-
mann C, Boston, Little Brown Co., 1992, pp 1267–1290levels at onset of the disease [14], whereas others found a
3. Nash M, Edelmann C, Bernstein J, Barnett H. The nephrotichigher incidence of frequent relapsers in boys or younger
syndrome, in Pediatric Kidney Disease, edited by Edelmann C,
children [12, 13]. Findings in the present study indicate Boston, Little Brown Co., 1992, pp 1247–1266
4. Andenmatten F, Bianchetti MG, Gerber HA, Zimmermann A,that the influence of sex and age at onset of the disease
Meregalli P, Luthy C, Oetliker OH: Outcome of idiopathicin the incidence of frequent relapses may depend on
childhood nephrotic syndrome: A 20 year experience. Scand J Urol
prednisolone dosage in the initial therapy. Nephrol 29:15–19, 1995
5. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsu-Adverse side effects were more frequent in Group 1
moto J, Ohnishi M, Yasaki T: Intermittent versus long-term taper-than in Group 2, although these side effects were mostly
ing prednisolone for initial therapy in children with idiopathic
mild and transient. It should be noted that striae, one of nephrotic syndrome. J Pediatr 112:122–126, 1988
6. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Short versusthe most significant, was only rarely observed in either
standard prednisone therapy for initial treatment of idiopathicgroup. The incidence of obesity and striae in Group 1 in
nephrotic syndrome in children. Lancet 1:380–383, 1988
the present study was approximately half of that in pa- 7. Ehrich JH, Brodehl J: Long versus standard prednisone therapy
for initial treatment of idiopathic nephrotic syndrome in children:tients treated with the same regimen in Ehrich and Bro-
Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatrdehl’s study [7]. Differences in the genetic and sociocul-
152:357–361, 1993
tural backgrounds of patients involved in the two studies 8. Ksiazek J, Wyszynska T: Short versus long initial prednisolone
treatment in steroid-sensitive nephrotic syndrome in children. Actapossibly may explain the different incidence of these side
Paediatr 84:889–893, 1995effects. It seems, in addition, likely that recommendation
9. Grupe W: Minimal change disease, in Textbook of Nephrology,
to avoid caloric overintake was effective in reducing the edited by Massry S, Glassock R, Baltimore, Williams & Wilkins,
1983, pp 6.27–6.33incidence of these side effects in the present study.
Hiraoka et al: Prednisolone dosage in nephrotic syndrome1252
10. Ooi B, Chen B, Tan K, Khoo O: Longitudinal studies of lipoid 18. Ponticelli C, Passerini P: Treatment of the nephrotic syndrome
associated with primary glomerulonephritis. Kidney Int 46:595–604,nephrosis. Arch Intern Med 130:883–886, 1972
11. Nolasco F, Cameron J, Heywood E: Adult-onset minimal-change 1994
19. A Report of the International Study of Kidney Disease in Children.nephrotic syndrome: A long-term follow-up. Kidney Int 29:1215–
1223, 1986 Nephrotic syndrome in children: A randomized trial comparing
two prednisone regimens in steroid-responsive patients who re-12. Lewis M, Baildom EM, Davis N, Houston IB, Postlethwaite RJ:
Nephrotic syndrome: From toddlers to twenties. Lancet 1:255–259, lapse early. J Pediatr 95:239–243, 1979
20. A report of Arbeitsgemeinschaft fur Padiatrische Nephrologie:1989
13. Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara Alternate-day versus intermittent prednisone in frequently relaps-
ing nephrotic syndrome. Lancet 1:401–403, 1979T, Uchiyama M: Influence of age at onset on the outcome of
steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467–470, 21. Ekka BK, Bagga A, Srivastava RN: Single- versus divided-dose
prednisolone therapy for relapses of nephrotic syndrome. Pediatr1998
14. A Report of the International Study of Kidney Disease in Children. Nephrol 11:597–599, 1997
22. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Effect of cyto-Early identification of frequent relapsers among children with mini-
mal change nephrotic syndrome. J Pediatr 101:514–518, 1982 toxic drugs in frequently relapsing nephrotic syndrome with and
without steroid dependence. N Engl J Med 306:451–454, 198215. Tarshish P, Tobin JN, Bernstein J, Edelmann CJ: Prognostic
significance of the early course of minimal change nephrotic syn- 23. Niaudet P: Comparison of cyclosporin and chlorambucil in the
treatment of steroid-dependent idiopathic nephrotic syndrome: Adrome: Report of the International Study of Kidney Disease in
Children. J Am Soc Nephrol 8:769–776, 1997 multicentre randomized controlled trial: The French Society of
Paediatric Nephrology. Pediatr Nephrol 6:1–3, 199216. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C,
Grassi C, Della Volpe M, Perfumo F, Petrone P, Picca M: 24. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gus-
mano R, Lama G, Zacchello G, Confalonieri R, Altieri P:Controlled trial of methylprednisolone pulses and low dose oral
prednisone for the minimal change nephrotic syndrome. BMJ Cyclosporin versus cyclophosphamide for patients with steroid-
dependent and frequently relapsing idiopathic nephrotic syn-291:1305–1308, 1985
17. Brodehl J: Conventional therapy for idiopathic nephrotic syn- drome: A multicentre randomized controlled trial. Nephrol Dial
Transplant 8:1326–1332, 1993drome in children. Clin Nephrol 35:S8–S15, 1991
